BIOA BioAge Labs, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1709941 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY45.3%
TTM net income YoY-42.2%
TTM EPS YoY-118.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,401.8%
Net margin-1,253.6%
FCF margin-1,197.8%
EBITDA margin—
Returns
ROE-34.6%
ROA-32.0%
ROIC (approx.)-52.9%
Asset turnover0.03x
Leverage & solvency
Liabilities / assets5.8%
Debt / equity0.00x
Current ratio15.51x
Interest coverage-913.20x
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio-1.6%
Payout ratio—
Capex / revenue5.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $298,000 | $2.45M | $2.77M | $3.08M | $2.05M | $2.41M | $1.45M | $0 |
| R&D expense | $30.23M | $24.36M | $20.41M | $24.50M | $18.51M | $19.84M | $11.11M | $19.23M |
| SG&A expense | $7.48M | $7.42M | $7.74M | $7.00M | $6.68M | $7.34M | $6.79M | $6.14M |
| Operating income | -$37.41M | -$29.33M | -$25.38M | -$28.42M | -$23.14M | -$24.77M | -$16.45M | -$25.36M |
| Interest expense | $0 | $1,000 | $39,000 | $92,000 | $149,000 | $201,000 | $255,000 | $319,000 |
| Net income | -$33.50M | -$26.10M | -$22.25M | -$25.94M | -$20.17M | -$21.56M | -$12.93M | -$21.13M |
| EBITDA | -$37.31M | — | — | -$28.32M | -$23.14M | — | — | -$25.26M |
| EPS (basic) | -0.73 | -0.58 | -0.52 | — | -0.56 | -0.60 | -0.36 | — |
| EPS (diluted) | -0.73 | -0.58 | -0.52 | — | -0.56 | -0.60 | -0.36 | — |
| Weighted avg. shares (diluted) | 45.91M | 44.84M | 42.48M | — | 35.85M | 35.85M | 35.85M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $52.67M | $73.96M | $241.78M | $188.89M | $215.57M | $220.33M | $257.49M | $354.35M |
| Short-term investments | $230.97M | $244.78M | $141.42M | $92.21M | $70.20M | $76.97M | $63.03M | $0 |
| Receivables | $565,000 | $625,000 | $709,000 | $769,000 | $515,000 | $603,000 | $361,000 | $0 |
| Current assets | $295.05M | $330.31M | $391.86M | $286.79M | $290.83M | $301.70M | $324.81M | $357.10M |
| PP&E, net | $1.13M | $1.21M | $1.11M | $963,000 | $973,000 | $974,000 | $929,000 | $591,000 |
| Total assets | $367.65M | $396.93M | $397.65M | $294.89M | $305.09M | $322.15M | $343.84M | $358.23M |
| Current liabilities | $19.03M | $19.22M | $15.83M | $20.14M | $24.49M | $22.84M | $23.74M | $27.77M |
| Short-term debt | $0 | $0 | $1.16M | $2.65M | $4.13M | $5.60M | $6.00M | $6.00M |
| Long-term debt | — | — | — | $0 | $0 | $0 | $1.06M | $2.50M |
| Total debt | — | — | — | $2.65M | $4.13M | $5.60M | $7.06M | $8.50M |
| Total liabilities | $21.20M | $22.02M | $18.53M | $22.84M | $27.63M | $27.37M | $30.67M | $35.11M |
| Shareholders' equity | $346.45M | $374.91M | $379.12M | $272.05M | $277.46M | $294.78M | $313.17M | $323.13M |
| Net debt | — | — | — | -$186.24M | -$211.45M | -$214.73M | -$250.43M | -$345.85M |
| Shares outstanding | 45.95M | 45.78M | 44.39M | 37.39M | 35.85M | 35.85M | 35.85M | 35.85M |
| Cash flow statement | ||||||||
| Operating cash flow | -$30.96M | -$19.26M | -$24.05M | -$28.25M | -$16.04M | -$19.97M | -$17.36M | -$5.14M |
| Capital expenditure | $18,000 | $328,000 | $26,000 | $112,000 | $22,000 | $159,000 | $426,000 | $26,000 |
| Free cash flow | -$30.98M | -$19.59M | -$24.07M | -$28.36M | -$16.07M | -$20.13M | -$17.79M | -$5.16M |
| Investing cash flow | $7.54M | -$164.51M | -$46.75M | -$14.43M | $12.84M | -$15.64M | -$77.99M | -$26,000 |
| Financing cash flow | $2.08M | $15.97M | $123.72M | $16.01M | -$1.54M | -$1.50M | -$1.50M | $24.90M |
| Depreciation & amortization | $100,000 | — | — | $100,000 | $0 | — | — | $100,000 |
| Stock-based compensation | $4.64M | $4.27M | $4.26M | $2.72M | $2.79M | $3.23M | $2.95M | $2.72M |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.